Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients

Phase 3

Conditions: Esophagus Cancer
Chemotherapy Effects

Interventions: Drug: Docetaxel
Drug: Fluorouracil
Drug: Cisplatin

First Posted Date: 2016-12-23

Last Posted Date: 2016-12-26

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 358

Registration Number: NCT03002064

Locations: 🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China

Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)

Phase 3

Active, not recruiting

Conditions: HNSCC

Interventions: Drug: Cisplatin
Drug: Cetuximab
Radiation: IMRT
Drug: avelumab

First Posted Date: 2016-12-21

Last Posted Date: 2024-07-10

Lead Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Target Recruit Count: 707

Registration Number: NCT02999087

Locations: 🇫🇷
Centre Hospitalier Bretagne Sud, Lorient, France

Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 1

Conditions: Head and Neck Cancers

Interventions: Drug: Durvalumab
Drug: Docetaxel
Drug: Cisplatin
Drug: 5 Fluorouracil

First Posted Date: 2016-12-20

Last Posted Date: 2019-01-03

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 36

Registration Number: NCT02997332

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)

Phase 3

Recruiting

Conditions: HNSCC

Interventions: Radiation: radiotherapy
Drug: Cisplatin

First Posted Date: 2016-12-20

Last Posted Date: 2024-07-10

Lead Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Target Recruit Count: 342

Registration Number: NCT02998385

Locations: 🇫🇷
Hôpital Bégin, Saint-Mandé, France

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Active, not recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Nivolumab
Drug: Cisplatin
Drug: Vinorelbine
Biological: Ipilimumab
Drug: Gemcitabine
Drug: Docetaxel
Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2016-12-20

Last Posted Date: 2023-10-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 505

Registration Number: NCT02998528

Locations: 🇺🇸
Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸
Local Institution - 0151, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0006, Boston, Massachusetts, United States

and more 132 locations

Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)

Phase 4

Conditions: Squamous Non-small-cell Lung Cancer

Interventions: Drug: Paclitaxel Liposome
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2016-12-19

Last Posted Date: 2020-02-13

Lead Sponsor: Nanjing Luye Sike Pharmaceutical Co., Ltd.

Target Recruit Count: 536

Registration Number: NCT02996214

A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma

Phase 2

Terminated

Conditions: Unresectable Intrahepatic Cholangiocarcinoma

Interventions: Drug: gemcitabine
Drug: Cisplatin
Drug: Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C

First Posted Date: 2016-12-15

Last Posted Date: 2019-12-30

Lead Sponsor: Yale University

Target Recruit Count: 1

Registration Number: NCT02994251

Locations: 🇺🇸
Smilow Cancer Center, New Haven, Connecticut, United States

Cisplatin + Radiation in SCCHN and Correlation with Oxidative Stress Markers

Phase 2

Active, not recruiting

Conditions: Carcinoma, Squamous Cell
Head and Neck Cancer

Interventions: Drug: Cisplatin
Radiation: XRT

First Posted Date: 2016-12-15

Last Posted Date: 2024-11-18

Lead Sponsor: Susanne Arnold

Target Recruit Count: 80

Registration Number: NCT02994069

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC

Phase 1

Terminated

Conditions: Biliary Tract Cancer

Interventions: Drug: Varlitinib
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2016-12-14

Last Posted Date: 2021-01-14

Lead Sponsor: ASLAN Pharmaceuticals

Target Recruit Count: 204

Registration Number: NCT02992340

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: BMX-001
Radiation: Radiation Therapy
Drug: Cisplatin

First Posted Date: 2016-12-13

Last Posted Date: 2023-03-15

Lead Sponsor: BioMimetix JV, LLC

Target Recruit Count: 29

Registration Number: NCT02990468

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
University of Florida- Gainesville, Gainesville, Florida, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy